PROTHENA CORPORATION PUBLIC LIMITED COMPANY Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $7.96 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-27
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $7.96M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $11.81M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $9.36M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $7.63M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $7.96M 10-K · filed 2026-02-27 |
| 2024-12-31 | $11.81M 10-K · filed 2026-02-27 |
| 2023-12-31 | $9.36M 10-K · filed 2025-02-27 |
| 2022-12-31 | $7.63M 10-K · filed 2024-02-22 |
| 2021-12-31 | $7.11M 10-K · filed 2023-02-28 |
| 2020-12-31 | $13.05M 10-K · filed 2022-02-25 |
| 2019-12-31 | $11.19M 10-K · filed 2021-02-26 |
| 2018-12-31 | $9.32M 10-K · filed 2020-03-03 |
| 2017-12-31 | $7.44M 10-K · filed 2019-03-15 |
| 2016-12-31 | $8.97M 10-K · filed 2018-02-26 |
| 2015-12-31 | $3.77M 10-K · filed 2017-02-27 |
| 2014-12-31 | $2.23M 10-K · filed 2016-02-25 |
| 2013-12-31 | $779.00K 10-K · filed 2015-03-13 |
| 2012-12-31 | $0.00 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |